Drug intelligence / Profile preview

MA34

Development stage: Discontinued
Lead developer: Johnson & Johnson
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Subcutaneous

Overview

MA34 is a biosimilar monoclonal antibody developed by Momenta Pharmaceuticals in collaboration with Baxter. It was intended for the treatment of autoimmune and inflammatory diseases. The drug acts as a tumor necrosis factor alpha (TNF-alpha) inhibitor. Its development was discontinued in Phase 1 for autoimmune disorders and inflammation in 2019.

Targets

TNFA (Tumor necrosis factor alpha (soluble))

Beyond the preview

Go deeper on MA34.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on MA34.

Explore the full profile